Mechanisms of Disease: The tissue kallikrein-kinin system in hypertension and vascular remodeling

Nature Clinical Practice Nephrology

Volumn 3, Issue 4, 2007, Pages 208-221

  Madeddu, Paolo ^a,b   Emanueli, Costanza ^a   El Dahr, Samir ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IRCCS MULTIMEDICA   (Italy)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiotensin; Bradykinin; Cardiovascular; Kallikrein; Kidney

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; B 9340; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; BRADYKININ ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; KININ; KININOGEN; LOSARTAN; MINERALOCORTICOID; N(G) NITROARGININE METHYL ESTER; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DNA MODIFICATION; DNA POLYMORPHISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC VARIABILITY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KNOCKOUT MOUSE; MOUSE STRAIN; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; RENAL PROTECTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM RETENTION; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENIC MOUSE; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 33947645406     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0444     Document Type: Review

References (161)

1. Bhoola KD et al. (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44: 1-80
2. Nolly H et al. (1990) A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats. Hypertension 16: 436-440
3. Madeddu P et al. (1994) A kallikrein-like enzyme in the aorta of normotensive and hypertensive rats. Hypertension 23: 899-902
4. Madeddu P et al. (1993) A kallikrein-like enzyme in human vascular tissue. Am J Hypertens 6: 344-348
5. Kemme M et al. (1999) Identification of immunoreactive tissue prokallikrein on the surface membrane of human neutrophils. Biol Chem 380: 1321-1328
6. Yayama K et al. (2003) Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 1593: 231-238
7. Yano Y et al. (2003) Immunohistochemical distributions of the tissue kallikrein-kinin system in ischemic and non-ischemic mouse heart. J Cardiovasc Pharmacol 42 (Suppl 1): S49-S53
8. Plendl J et al. (2000) Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 381: 1103-1115
9. Mahabeer R and Bhoola KD (2000) Kallikrein and kinin receptor genes. Pharmacol Ther 88: 77-89
10. Chen VC et al. (2000) A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. J Biol Chem 275: 40371-40377
11. Campbell DJ (2001) The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 28: 1060-1065
12. Ura N et al. (1994) The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens 16: 799-808
13. Hasan AA et al. (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94: 517-528
14. Marceau F and Regoli D (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3: 845-852
15. Leeb-Lundberg LM et al. (2005) International union of pharmacology. XLV: classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77
16. Fleming I et al. (1995) Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of mitogen-activated protein kinases. Circ Res 76: 522-529
17. Fleming I et al. (1996) Interdependence of calcium signaling and protein tyrosine phosphorylation in human endothelial cells. J Biol Chem 271: 11009-11015
18. Lal MA et al. (1998) A role for PKC epsilon and MAP kinase in bradykinin-induced arachidonic acid release in rabbit CCD cells. Am J Physiol 274: F728-735
19. Busse R and Fleming I (1995) Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 27: 331-340
20. Vanhoutte PM et al. (1995) Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 76: E3-E12
21. Harris MB et al. (2001) Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 276: 16587-16591
22. Emanueli C et al. (2004) Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110: 1638-1644
23. 2 receptor with endothelial nitric-oxide synthase. J Biol Chem 273: 24025-24029
24. Feron O and Balligand JL (2006) Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 69: 788-797
25. Venema RC (2002) Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int Immunopharmacol 2: 1755-1762
26. Ignarro LJ et al. (1987) Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am J Physiol 253: H1074-H1082
27. Batenburg WW et al. (2004) Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF? Br J Pharmacol 142: 125-135
28. Taddei S et al. (1999) Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 100: 1400-1405
29. 2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 58: 828-836
30. Marceau F and Bachvarov DR (1998) Kinin receptors. Clin Rev Allergy Immunol 16: 385-401
31. 2+ signaling in single cultured vascular smooth muscle cells. Mol Pharmacol 50: 128-139
32. 2-receptor antagonist. Br J Clin Pharmacol 38: 317-321
33. Panza JA et al. (1995) Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91: 1732-1738
34. Groves P et al. (1995) Role of endogenous bradykinin in human coronary vasomotor control. Circulation 92: 3424-3430
35. Kuga T et al. (1995) Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation 92: 183-189
36. Granger JP and Hall JE (1985) Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol 248: F87-F92
37. Campbell DJ et al. (2005) Losartan increases bradykinin levels in hypertensive humans. Circulation 111: 315-320
38. Madeddu P et al. (1987) The effects of aprotinin, a kallikrein inhibitor, on renin release and urinary sodium excretion in mild essential hypertensives. J Hypertens 5: 581-586
39. Chao J et al. (1997) Kallistatin is a potent new vasodilator. J Clin Invest 100: 11-17
40. Vavrek RJ and Stewart JM (1985) Competitive antagonists of bradykinin. Peptides 6: 161-164
41. Lembeck F et al. (1991) New, long-acting, potent bradykinin antagonists. Br J Pharmacol 102: 297-304
42. 2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 129: 77-86
43. 2 receptor. J Med Chem 43: 769-771
44. 2 antagonist, on kinin-induced hypotension, visceral and peripheral oedema formation and bronchoconstriction. Br J Pharmacol 120: 933-939
45. 2 receptor antagonist. Immunopharmacology 43: 187-194
46. Carbonell LF et al. (1988) Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 11: 239-243
47. 2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 25: 453-459
48. 2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 36: 132-136
49. 2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension 23: 646-652
50. 2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension 21: 980-984
51. 2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab 291: E268-E274
52. 2 receptor functional heterodimerization. Hypertension 48: 316-322
53. 2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 26: 185-192
54. Hunt SC et al. (1993) Environmental determinants of urinary kallikrein excretion. Am J Hypertens 6: 226-233
55. Linz W et al. (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25-49
56. Landmesser U and Drexler H (2006) Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens 24 (Suppl 1): S39-S43
57. Gainer JV et al. (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339: 1285-1292
58. Fenoy FJ et al. (1991) Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 17: 1038-1044
59. Matsuda H et al. (1999) Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 10: 2272-2282
60. Matsuda H et al. (2004) Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension 43: 603-609
61. Tornel J et al. (2000) Role of kinins in the control of renal papillary blood flow, pressure natriuresis, and arterial pressure. Circ Res 86: 589-595
62. 2 kinin receptor gene knockout mice. Circ Res 88: 1072-1079
63. 2-receptor expression at different time points after induction of myocardial infarction. J Hypertens 18: 223-228
64. 1-receptor expression after myocardial infarction. Br J Pharmacol 129: 1537-1538
65. Witherow FN et al. (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104: 2177-2181
66. Davie AP et al. (1999) Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 100: 268-273
67. Emanueli C et al. (1998) Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31: 1299-1304
68. Koga N et al. (1993) Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor. ASAIO J 39: M288-M291
69. Davidson DC et al. (1994) Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis. Lancet 343: 1575
70. Fox AJ et al. (1996) Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 2: 814-817
71. 9-bradykinin. J Pharmacol Exp Ther 303: 232-237
72. 2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther 78: 477-485
73. Madeddu P et al. (1990) Brain kinins are responsible for the pressor effect of intracerebroventricular captopril in spontaneously hypertensive rats. Hypertension 15: 407-412
74. 1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br J Pharmacol 126: 1769-1776
75. Madeddu P et al. (1996) Antisense inhibition of the brain kallikrein-kinin system. Hypertension 28: 980-987
76. Woodley-Miller C et al. (1989) Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens 7: 865-871
77. Gavras I and Gavras H (1988) Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int 26 (Suppl): S60-S62
78. Madeddu P et al. (1997) Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29: 471-477
79. Madeddu P et al. (2001) Renal phenotype of low kallikrein rats. Kidney Int 59: 2233-2242
80. Margolius HS (1998) Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 16: 337-349
81. Zinner SH et al. (1978) Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation 58: 908-915
82. Berge KE and Berg K (1993) No effect of TaqI polymorphism at the human renal kallikrein (KLK1) locus on normal blood pressure level or variability. Clin Genet 44: 196-202
83. Friend LR et al. (1996) Examination of the role of nitric oxide synthase and renal kallikrein as candidate genes for essential hypertension. Clin Exp Pharmacol Physiol 23: 564-566
84. Yu H et al. (1998) Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31: 906-911
85. Hua H et al. (2005) Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension. J Hum Hypertens 19: 715-721
86. Williams RR et al. (1993) Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am J Hypertens 6: S319-S327
87. Williams RR et al. (1991) Genetic traits related to hypertension and electrolyte metabolism. Hypertension 17 (Suppl 1): S69-S73
88. Berry TD et al. (1989) A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13: 3-8
89. Slim R et al. (2002) Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 13: 968-976
90. Azizi M et al. (2005) Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 115: 780-787
91. Rossi GP et al. (2006) Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects. J Hypertens 24: 1955-1963
92. Majima M et al. (1994) Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24: 111-119
93. Pravenec M et al. (1991) Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17: 242-246
94. Rigat B et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346
95. Danser AH et al. (1995) Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 92: 1387-1388
96. Myerson SG et al. (2001) Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. Circulation 103: 226-230
97. Rossi GP et al. (2001) Exclusion of the ACE D/I gene polymorphism as a determinant of endothelial dysfunction. Hypertension 37: 293-300
98. 2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 99: 134-146
99. Brull D et al. (2001) Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet 358: 1155-1156
100. 2 and association with hypertension. J Hypertens 23: 55-62
101. Dhamrait SS et al. (2003) Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J 24: 1672-1680
102. Pesquero JB and Bader M (2006) Genetically altered animal models in the kallikrein-kinin system. Biol Chem 387: 119-126
103. Wang J et al. (1994) Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23: 236-243
104. Chao J and Chao L (1996) Functional analysis of human tissue kallikrein in transgenic mouse models. Hypertension 27: 491-494
105. Silva JA, Jr et al. (2000) Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 14: 1858-1860
106. 2 receptor. Hypertension 29: 488-493
107. Pinto YM et al. (2000) Increased kallikrein expression protects against cardiac ischemia. FASEB J 14: 1861-1863
108. 2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371-379
109. Tschope C et al. (2004) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18: 828-835
110. 2 receptor transgenic mice. Am J Physiol Renal Physiol 278: F484-F491
111. Meneton P et al. (2001) Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98: 2634-2639
112. Han ED et al. (2002) Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109: 1057-1063
113. Bergaya S et al. (2001) Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88: 593-599
114. Hilgers RH et al. (2003) Uterine artery structural and functional changes during pregnancy in tissue kallikrein-deficient mice. Arterioscler Thromb Vasc Biol 23: 1826-1832
115. Bergaya S et al. (2004) Role of tissue kallikrein in response to flow in mouse resistance arteries. J Hypertens 22: 745-750
116. Griol-Charhbili V et al. (2005) Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 19: 1172-1174
117. 2 receptor- and tissue kallikrein-deficient mice. Hypertension 40: 90-95
118. Krege JH et al. (1997) Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29: 150-157
119. Huang W et al. (2001) Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 98: 13330-13334
120. Tian B et al. (1997) Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. Hypertension 30: 128-133
121. Xiao HD et al. (2003) Role of bradykinin in angiotensin-converting enzyme knockout mice. Am J Physiol Heart Circ Physiol 284: H1969-H1977
122. 2-receptor gene. Circulation 96: 3570-3578
123. 2 receptor of bradykinin in insulin sensitivity. Hypertension 38: 1355-1360
124. Lu B et al. (1997) The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med 3: 904-907
125. 2 receptor knockout mice. Biochem Biophys Res Commun 224: 625-630
126. Emanueli C and Madeddu P (1999) Role of the kallikrein-kinin system in the maturation of cardiovascular phenotype. Am J Hypertens 12: 988-999
127. 2 receptor knockout mice. Hypertension 41: 1151-1155
128. 2 receptor. Hypertension 37: 1473-1479
129. 2 receptor. Am J Physiol Heart Circ Physiol 284: H1904-H1908
130. Wang Q et al. (2002) Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes. J Am Soc Nephrol 13: 1509-1516
131. 2 receptor knockout mice. Hypertension 35: 391-396
132. Harrison-Bernard LM et al. (2003) Renal segmental microvascular responses to ANG II in AT1A receptor null mice. Am J Physiol Renal Physiol 284: F538-F545
133. 2 receptor gene. Hypertension 31: 1278-1283
134. 2-receptor knockout mice. Hypertension 32: 503-509
135. 2 receptor null mice. Hypertension 34: 176-180
136. 2 receptor. J Hypertens 21: 1531-1538
137. 2 receptor. Hypertension 47: 752-761
138. 2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108: 192-199
139. 1 receptors. Proc Natl Acad Sci USA 97: 8140-8145
140. Emanueli C and Madeddu P (2001) Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol Sci 22: 478-484
141. 1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45: 747-753
142. 2 receptor knockout mice reveals comparable modulation of functionally related genes. Biol Chem 387: 15-22
143. Xiong W et al. (1995) Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 25: 715-719
144. Wang C et al. (1995) Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95: 1710-1716
145. Jin L et al. (1997) Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 8: 1753-1761
146. Chao J et al. (1998) Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 54: 1250-1260
147. Yayama K et al. (1998) Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31: 1104-1110
148. Wolf WC et al. (2000) Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58: 730-739
149. Zhang JJ et al. (1999) Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke 30: 1925-1931
150. Xia CF et al. (2004) Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43: 452-459
151. Xia CF et al. (2006) Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 17: 206-219
152. Bledsoe G et al. (2006) Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther 17: 545-555
153. Emanueli C et al. (2001) Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 38: 136-141
154. Spillman F et al. (2006) Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen Med 1: 235-254
155. Emanueli C et al. (2001) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103: 125-132
156. Emanueli C et al. (2000) Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 20: 2379-2385
157. Emanueli C et al. (2004) Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110: 1638-1644
158. 1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15: 1487-1489
159. Ebrahimian TG et al. (2005) Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 25: 65-70
160. 1 receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol 135: 87-92
161. Dedio J et al. (2001) Tissue kallikrein KLK1 is expressed de novo in endothelial cells and mediates relaxation of human umbilical veins. Biol Chem 382: 1483-1490